SynTra
Synthetic Transposons for Non-Viral-Gene Transfer
The Challenge
Cell and gene therapies hold great potential, but their impact is still constrained by the high cost and complexity of vector manufacturing. Viral vector production, in particular, remains expensive, difficult to scale, and too inefficient to support broad treatment access. As a result, the promises of individualised therapies, such as TCR-treatments, remain limited by current manufacturing bottlenecks.
The Solution
SynTra addresses this challenge by developing a fully synthetic, automated production process for tailor-made DNA vectors, designed to meet the unique needs of each individual therapy. By shifting away from viral vectors toward the Sleeping Beauty transposon system — a proven, non-viral approach for stable gene delivery — SynTra dramatically simplifies the manufacturing workflow. The result is a flexible platform capable of producing patient-specific vectors at a fraction of today’s cost and complexity.
Looking For
- Co-development partners
- Pilot partner
- Investors
Technology
SynTra is also available as technology asset.
